Compare
Veradermics, Inc vs Whitehawk Therapeutics, Inc. vs Xilio Therapeutics, Inc. vs XBiotech Inc.
| Latest fiscal year | Veradermics, Inc MANE | Whitehawk Therapeutics, Inc. WHWK | Xilio Therapeutics, Inc. XLO | XBiotech Inc. XBIT |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $7.14M | $43.77M | n/a |
| Revenue growth (YoY) | n/a | -72.5% | +589.9% | n/a |
| Gross margin | n/a | 89.4% (computed) | n/a | n/a |
| Operating margin | n/a | n/m | -95.9% | n/a |
| Net margin | n/a | -288.3% | -80.1% | n/a |
| Net income | -$70.00M | -$20.60M | -$35.04M | -$45.54M |
| EPS (Diluted) | -$111.91 | -$0.33 | -$4.19 | -$1.49 |
| Operating cash flow | -$71.60M | -$97.43M | -$4.99M | -$39.92M |
| Free cash flow | -$71.63M | -$97.98M | -$5.51M | -$40.21M |
| Cash & equivalents | $21.77M | $37.57M | $137.53M | $125.55M |
| Total assets | $152.62M | $150.83M | $154.69M | $150.08M |
| Total liabilities | $9.16M | $14.52M | $119.41M | $9.73M |
| Shareholders' equity | -$121.01M | $136.31M | $35.27M | $140.35M |
| Return on year-end equity | n/a | -15.1% | -99.3% | -32.4% |
| Shares outstanding | 749.8K | 47.15M | 4.53M | 30.49M |
Revenue, most recent five fiscal years
| Fiscal year | Veradermics, Inc | Whitehawk Therapeutics, Inc. | Xilio Therapeutics, Inc. | XBiotech Inc. |
|---|---|---|---|---|
| Latest | n/a | $7.14M Ended 2025-12-31 | $43.77M Ended 2025-12-31 | $0 Ended 2023-12-31 |
| 1 year earlier | n/a | $25.98M Ended 2024-12-31 | $6.34M Ended 2024-12-31 | $4.01M Ended 2022-12-31 |
| 2 years earlier | n/a | $24.35M Ended 2023-12-31 | n/a | $18.39M Ended 2021-12-31 |
| 3 years earlier | n/a | $15.22M Ended 2022-12-31 | n/a | $44.00M Ended 2020-12-31 |
| 4 years earlier | n/a | $14.00M Ended 2021-12-31 | n/a | $0 Ended 2019-12-31 |